GO:0047555 3',5'-cyclic-GMP phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047555 describes the enzymatic activity that hydrolyzes 3',5'-cyclic GMP to GMP and H+, a key step in cGMP signal termination [1, 3, 5].
• This activity is distinct from cAMP phosphodiesterase, though some enzymes exhibit dual specificity, as shown in neuroblastoma differentiation models.
• Dysregulated cGMP phosphodiesterase activity is linked to cardiovascular disease, retinal disorders, and cancer, with altered serum activity in phaeochromocytoma and myocardial infarction [1, 4].
• The absence of functional PDE6 in Y79 retinoblastoma cells highlights the importance of this activity in retinal biology.
• Small-molecule inhibitors of cGMP phosphodiesterase, such as 6-phenylpyrazolo[3,4-d]pyrimidones, are valuable research tools and therapeutic leads [3, 5].
• Studying GO:0047555 requires precise enzymatic assays, often using radiolabeled c-di-GMP or cGMP, and can be combined with CRISPR-based gene editing for causal validation.
Description
3',5'-cyclic-GMP phosphodiesterase activity (GO:0047555) is a molecular function that catalyzes the hydrolysis of cyclic guanosine monophosphate (cGMP) to GMP and a proton [1, 3]. This activity is essential for terminating cGMP signaling, which regulates diverse physiological processes including vascular smooth muscle relaxation, phototransduction, and neuronal plasticity [5, 6]. Researchers study this activity to understand how cells control cGMP levels and to develop therapeutics for diseases such as hypertension, heart failure, and retinal degeneration [1, 4]. The enzyme activity was first characterized in serum and tissues, and later linked to specific phosphodiesterase (PDE) families [1, 2]. In this article, we provide a comprehensive overview of GO:0047555, covering its definition, mechanism, key genes, disease relevance, and modern research methods including CRISPR-based models.
3',5'-cyclic-GMP phosphodiesterase activity At A Glance
| GO ID | GO:0047555 |
|---|---|
| GO term | 3',5'-cyclic-GMP phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | cGMP-PDE; cGMP phosphodiesterase activity; cyclic GMP phosphodiesterase activity; 3',5'-cyclic-GMP 5'-nucleotidohydrolase activity |
| Major function | Hydrolysis of 3',5'-cyclic GMP to GMP and H+ |
| Reaction | 3',5'-cyclic GMP + H2O = GMP + H+ |
| Substrate | 3',5'-cyclic GMP (cGMP) |
| Product | GMP and H+ |
| Cofactors | Some isoforms require divalent cations such as Mg2+ or Mn2+; calcium-dependent regulation has been reported. |
What Is GO:0047555?
According to the Gene Ontology, GO:0047555 is defined as the catalysis of the reaction: 3',5'-cyclic GMP + H2O = GMP + H+. In other words, it is the enzymatic activity that breaks down cGMP, a cyclic nucleotide second messenger, into its non-cyclic form GMP. This activity is also known by synonyms such as cGMP-PDE, cGMP phosphodiesterase activity, and cyclic GMP phosphodiesterase activity. It is a molecular function term, meaning it describes what a gene product does at the biochemical level, rather than a biological process or cellular component.
Why Is 3',5'-cyclic-GMP phosphodiesterase activity Important in Cell Biology?
GO:0047555 is critically important because cGMP is a central second messenger in many physiological systems, and its precise regulation by phosphodiesterases is essential for normal function. Aberrant cGMP phosphodiesterase activity has been implicated in cardiovascular diseases, retinal disorders, and cancer, making it a target for drug discovery [1, 3, 4]. For researchers, understanding this activity provides insights into signal transduction, enzyme kinetics, and the development of selective inhibitors. Moreover, the availability of CRISPR tools allows for precise genetic manipulation of PDE genes to study their roles in health and disease.
• Regulates cGMP levels in vascular smooth muscle, affecting blood pressure and cardiac contractility.
• Plays a key role in phototransduction in the retina; defects are linked to retinal degeneration.
• Involved in neuronal differentiation and plasticity, as shown in neuroblastoma models.
• Altered serum activity is observed in phaeochromocytoma and myocardial infarction, suggesting biomarker potential [1, 4].
• Target for antiplatelet and cardiovascular drugs, such as CCT-62.
• Small-molecule inhibitors are used to probe cGMP signaling in cancer and other diseases.
• Provides a paradigm for studying enzyme kinetics and regulation by calcium and potassium ions.
• CRISPR-based knockout of PDE genes can reveal isoform-specific functions.
• High-throughput screening for modulators of this activity can identify new therapeutic leads.
• Understanding cGMP phosphodiesterase activity is essential for interpreting cGMP-mediated signaling in diverse cell types [5, 6].
What Happens During 3',5'-cyclic-GMP phosphodiesterase activity?
Substrate Binding and Catalysis
In simple terms: The enzyme grabs cGMP and breaks it apart using water.
The enzyme binds its substrate, 3',5'-cyclic GMP, in the active site. Through a hydrolysis reaction, the cyclic phosphate bond is cleaved, producing GMP and a proton [1, 3]. This reaction is highly specific for cGMP, although some phosphodiesterases can also hydrolyze cAMP. The catalytic mechanism often involves divalent metal ions that activate a water molecule for nucleophilic attack.
Regulation by Calcium and Potassium Ions
In simple terms: Calcium and potassium levels can change how fast the enzyme works.
Calcium-dependent 3',5'-cyclic nucleotide phosphodiesterase activity is inhibited by physiological levels of potassium ions, as shown in early biochemical studies. This suggests that ionic conditions within cells can modulate enzyme activity, linking cGMP hydrolysis to cellular excitability and ion homeostasis.
Induction During Differentiation
In simple terms: When cells differentiate, they make more of this enzyme.
In neuroblastoma cell lines, both cAMP and cGMP phosphodiesterase activities are induced under differentiating conditions, indicating that cGMP breakdown is upregulated during neuronal maturation. This induction may be important for shaping cGMP signals that guide differentiation processes.
Inhibition by Small Molecules
In simple terms: Certain drugs can block this enzyme, keeping cGMP levels high.
A series of 6-phenylpyrazolo[3,4-d]pyrimidones were synthesized and shown to inhibit cGMP phosphodiesterase activity. Another compound, CCT-62, inhibits both cAMP and cGMP phosphodiesterases and exhibits antiplatelet effects. These inhibitors are valuable for dissecting cGMP signaling pathways and have therapeutic potential.
Assays for Measuring Activity
In simple terms: Scientists use radioactive or fluorescent methods to measure how fast cGMP is broken down.
A method for synthesizing [(32)P]-c-di-GMP allows for determination of diguanylate cyclase and phosphodiesterase activities. Although this assay targets c-di-GMP, similar principles apply to cGMP phosphodiesterase assays, which often use radiolabeled cGMP or coupled enzyme systems to quantify activity.
Key Genes Involved in GO:0047555 3',5'-cyclic-GMP phosphodiesterase activity
The following genes encode enzymes or subunits that possess or regulate 3',5'-cyclic-GMP phosphodiesterase activity, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE5A | cGMP-specific phosphodiesterase; hydrolyzes cGMP in vascular smooth muscle | Target for erectile dysfunction and pulmonary hypertension drugs; studied in cardiovascular research. |
| PDE6A | Rod photoreceptor cGMP phosphodiesterase subunit | Mutations cause retinitis pigmentosa; absence of functional PDE6 in Y79 retinoblastoma cells. |
| PDE6B | Rod photoreceptor cGMP phosphodiesterase subunit | Linked to retinal degeneration; model for gene therapy. |
| PDE6C | Cone photoreceptor cGMP phosphodiesterase subunit | Associated with cone dystrophy; studied in retinal biology. |
| PDE9A | High-affinity cGMP-specific phosphodiesterase | Involved in neuronal cGMP signaling; potential target for cognition enhancement. |
| PDE10A | Dual-specificity phosphodiesterase (cAMP and cGMP) | Expressed in striatum; studied in schizophrenia and Huntington's disease. |
| PDE11A | Dual-specificity phosphodiesterase | Associated with adrenal hyperplasia and mood disorders. |
| PDE1A | Calcium/calmodulin-dependent phosphodiesterase | Regulated by calcium; involved in smooth muscle contraction. |
| PDE1B | Calcium/calmodulin-dependent phosphodiesterase | Neuronal expression; linked to synaptic plasticity. |
| PDE1C | Calcium/calmodulin-dependent phosphodiesterase | Role in vascular and airway smooth muscle. |
| PDE2A | cGMP-stimulated phosphodiesterase | Regulates cGMP and cAMP cross-talk; expressed in adrenal gland and brain. |
| PDE3A | cGMP-inhibited phosphodiesterase | Important in cardiac muscle and platelets; target of milrinone. |
| PDE3B | cGMP-inhibited phosphodiesterase | Insulin secretion and lipolysis; metabolic research. |
| PDE4A | cAMP-specific phosphodiesterase (some cGMP sensitivity) | Inflammatory diseases; not a primary cGMP PDE but can be affected. |
| PDE7A | cAMP-specific phosphodiesterase | T-cell activation; less direct role in cGMP hydrolysis. |
| PDE8A | cAMP-specific phosphodiesterase | Thyroid and testis; not a major cGMP PDE. |
| PDE9A | cGMP-specific phosphodiesterase | Cognitive disorders; target for PDE9 inhibitors. |
| PDE5A | cGMP-specific phosphodiesterase | Also listed for emphasis; key isoform in penile corpus cavernosum. |
How Is 3',5'-cyclic-GMP phosphodiesterase activity Regulated?
The activity of 3',5'-cyclic-GMP phosphodiesterase is regulated at multiple levels. Calcium and calmodulin can stimulate certain isoforms, such as PDE1, while physiological potassium concentrations inhibit basal activity. In neuroblastoma cells, differentiation stimuli induce both cAMP and cGMP phosphodiesterase activities, suggesting transcriptional regulation. Additionally, cGMP itself can feedback to regulate phosphodiesterases, and cross-talk with cAMP pathways modulates overall activity. Small-molecule inhibitors and activators further fine-tune enzyme function in research and therapeutic settings.
3',5'-cyclic-GMP phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE5A | Pulmonary hypertension, erectile dysfunction | Knockout mouse; overexpression in smooth muscle cells |
| PDE6A | Retinitis pigmentosa | Knock-in mouse with patient mutation; retinal organoids |
| PDE6B | Retinal degeneration | CRISPR knockout in Y79 cells; AAV gene therapy models |
| PDE9A | Cognitive impairment, Alzheimer's disease | Conditional knockout in neurons; behavioral tests |
| PDE10A | Schizophrenia, Huntington's disease | Knockout rat; striatal cell models |
Cardiovascular Disease
Serum cyclic 3',5'-nucleotide phosphodiesterase activity is elevated in patients with myocardial infarction, suggesting a role in cardiac stress responses. cGMP phosphodiesterases, particularly PDE5A, regulate vascular tone and are targets for drugs treating pulmonary hypertension and erectile dysfunction. Dysregulated cGMP hydrolysis contributes to endothelial dysfunction and heart failure.
Retinal Degeneration
Mutations in PDE6 subunits, which possess cGMP phosphodiesterase activity, cause retinitis pigmentosa and cone dystrophy. The absence of functional PDE6 in Y79 retinoblastoma cells highlights the importance of this activity in retinal cell biology and disease.
Cancer and Neuroendocrine Tumors
High activity of cyclic 3',5'-nucleotide phosphodiesterase has been reported in sera of patients with phaeochromocytoma, indicating potential as a tumor marker. In neuroblastoma, differentiation induces phosphodiesterase activities, linking cGMP breakdown to tumor cell maturation. Modulating cGMP phosphodiesterase activity may influence cancer cell proliferation and survival.
Neurological and Psychiatric Disorders
cGMP phosphodiesterases are expressed in the brain and regulate synaptic plasticity. PDE9A and PDE10A are being investigated as targets for cognitive disorders and schizophrenia. Induction of phosphodiesterase activity during neuronal differentiation suggests roles in brain development.
From 3',5'-cyclic-GMP phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDE5A affect cGMP levels and vascular tone? | PDE5A knockout mouse or CRISPR KO in endothelial cells |
| Can a point mutation in PDE6B mimic retinitis pigmentosa? | Knock-in mouse carrying patient mutation; iPSC-derived photoreceptors |
| What is the effect of PDE9A overexpression on synaptic plasticity? | AAV-mediated overexpression in mouse hippocampus |
| How does tagging PDE5A with GFP affect its localization? | CRISPR knock-in of GFP tag in cell lines |
| Which genes regulate cGMP phosphodiesterase activity? | CRISPR library screening with cGMP biosensors |
| Can small molecules selectively inhibit PDE isoforms? | High-throughput enzymatic assays using recombinant enzymes |
How to Study the 3',5'-cyclic-GMP phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioenzymatic assay | Conversion of [3H]-cGMP to [3H]-GMP | Kinetic analysis of purified PDEs |
| Fluorescence polarization | Binding of fluorescent cGMP analogs | High-throughput screening for inhibitors |
| CRISPR knockout | Loss of gene function | Validating PDE isoform-specific roles |
| Western blot | Protein expression levels | Confirming knockout or overexpression |
| cGMP biosensor imaging | Intracellular cGMP dynamics | Live-cell signaling studies |
| RNA-seq | Transcriptional changes upon PDE modulation | Identifying downstream pathways |
| X-ray crystallography | Three-dimensional structure of PDE | Structure-based drug design |
Enzymatic Activity Assays
Direct measurement of 3',5'-cyclic-GMP phosphodiesterase activity is typically performed using radiolabeled cGMP or coupled enzyme systems. A method for synthesizing [(32)P]-c-di-GMP has been adapted for phosphodiesterase activity determinations. These assays quantify the conversion of cGMP to GMP and are essential for kinetic studies and inhibitor screening.
CRISPR-Based Genetic Models
CRISPR/Cas9 technology enables the generation of knockout, point-mutation, and knock-in cell lines and animal models to study the function of specific PDE genes. For example, knocking out PDE6 subunits in retinoblastoma cells can mimic the absence of functional PDE6 observed in Y79 cells. These models allow causal testing of gene function in cGMP signaling.
Biochemical and Structural Approaches
Purification of recombinant phosphodiesterases and determination of their crystal structures provide insights into substrate specificity and catalytic mechanism. Calcium-dependent regulation and potassium inhibition have been characterized biochemically. Such studies guide the design of selective inhibitors.
Cell-Based Signaling Assays
Live-cell imaging with cGMP biosensors (e.g., cGES-DE5) allows real-time monitoring of cGMP dynamics upon phosphodiesterase modulation. Neuroblastoma differentiation models have been used to study induction of phosphodiesterase activities. These assays link enzyme activity to physiological outcomes.
How CRISPR Can Be Used to Study GO:0047555 3',5'-cyclic-GMP phosphodiesterase activity
Knockout
CRISPR knockout of PDE genes (e.g., PDE5A, PDE6A) eliminates enzyme activity, allowing researchers to study the consequences of loss of cGMP hydrolysis. For instance, knocking out PDE6B in retinal cells can model retinitis pigmentosa. Knockout models are essential for target validation in drug discovery.
Point Mutation
Introducing disease-associated point mutations (e.g., in PDE6B) via CRISPR base editing or homology-directed repair creates isogenic models that mimic human mutations. These models help dissect how specific amino acid changes affect catalytic activity and protein stability, as seen in retinal degeneration.
Knock-in
Knock-in of tags (e.g., GFP, FLAG) or reporter genes into endogenous PDE loci enables real-time tracking of protein localization and expression. Tagged PDE5A can be used to study its subcellular distribution in vascular smooth muscle cells. Knock-in of patient mutations also provides accurate disease models.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of PDE genes increases enzyme levels, allowing study of gain-of-function effects. Overexpressing PDE9A in neurons can enhance cGMP breakdown and affect synaptic plasticity. Overexpression models complement knockout studies to reveal bidirectional regulation.
How EDITGENE Supports 3',5'-cyclic-GMP phosphodiesterase activity Research
Researchers studying 3',5'-cyclic-GMP phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in cGMP signaling, disease pathogenesis, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for 3',5'-cyclic-GMP phosphodiesterase activity research.
Frequently Asked Questions About 3',5'-cyclic-GMP phosphodiesterase activity
What is 3',5'-cyclic-GMP phosphodiesterase activity?
It is the enzymatic activity that hydrolyzes cyclic GMP (cGMP) to GMP and H+, terminating cGMP signaling. This activity is classified as GO:0047555 in the Gene Ontology [1, 3].
What genes are involved in 3',5'-cyclic-GMP phosphodiesterase activity?
Key genes include PDE5A, PDE6A, PDE6B, PDE6C, PDE9A, PDE10A, and PDE11A, among others. These encode phosphodiesterase enzymes that specifically or preferentially hydrolyze cGMP [5, 6].
How is cGMP phosphodiesterase activity measured?
Common methods include radioenzymatic assays using [3H]-cGMP, fluorescence polarization, and coupled enzyme systems. A protocol for synthesizing [(32)P]-c-di-GMP has been adapted for phosphodiesterase assays.
What diseases are associated with cGMP phosphodiesterase dysfunction?
Dysfunction is linked to cardiovascular diseases (e.g., myocardial infarction), retinal degeneration (e.g., retinitis pigmentosa), and cancer (e.g., phaeochromocytoma) [1, 4, 6].
Can CRISPR be used to study cGMP phosphodiesterase activity?
Yes, CRISPR knockout, point mutation, and knock-in models allow precise manipulation of PDE genes to study their function in cGMP signaling and disease.
What are inhibitors of cGMP phosphodiesterase?
Small molecules such as 6-phenylpyrazolo[3,4-d]pyrimidones and CCT-62 inhibit cGMP phosphodiesterase activity and are used in research and therapy [3, 5].
How is cGMP phosphodiesterase activity regulated?
It is regulated by calcium/calmodulin, potassium ions, differentiation signals, and feedback from cyclic nucleotides. For example, physiological potassium levels inhibit basal activity.
Is cGMP phosphodiesterase activity the same as cAMP phosphodiesterase?
No, they are distinct activities, though some enzymes (e.g., PDE1, PDE2, PDE3) can hydrolyze both cyclic nucleotides. GO:0047555 specifically refers to cGMP hydrolysis.
What is the role of cGMP phosphodiesterase in the retina?
In photoreceptors, PDE6 hydrolyzes cGMP to close cGMP-gated channels and terminate the light response. Mutations in PDE6 subunits cause retinal degeneration.
How can I create a knockout of a PDE gene?
EDITGENE provides custom CRISPR knockout services for PDE genes in various cell types, with validation by sequencing and functional assays.
Conclusion
3',5'-cyclic-GMP phosphodiesterase activity (GO:0047555) is a fundamental enzymatic function that controls cGMP signaling in health and disease. From cardiovascular regulation to retinal phototransduction and neuronal differentiation, this activity is indispensable. The availability of CRISPR-based models and small-molecule inhibitors has accelerated research, revealing new therapeutic opportunities. Continued investigation of this activity will deepen our understanding of cGMP biology and yield novel treatments for related disorders.
References
- 1. Nakai A et al.. 1986. High activity of cyclic 3',5'-nucleotide phosphodiesterase in sera of patient with phaeochromocytoma.. Clin Endocrinol (Oxf) 24(4):409-14 PMID: 3017609
- 2. Davis CW et al.. 1978. Calcium-dependent 3':5'-cyclic nucleotide phosphodiesterase. Inhibition of basal activity at physiological levels of potassium ions.. J Biol Chem 253(24):8683-6 PMID: 214428
- 3. Dumaître B et al.. 1996. Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.. J Med Chem 39(8):1635-44 PMID: 8648603
- 4. Nagasaka A et al.. 1985. Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.. Acta Cardiol 40(6):613-20 PMID: 3006409
- 5. Liao CH et al.. 1998. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).. Eur J Pharmacol 349(1):107-14 PMID: 9669503
- 6. White JB et al.. 2004. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.. Mol Vis 10:738-49 PMID: 15480303
- 7. Giorgi M et al.. 1997. Induction of cyclic AMP and cyclic GMP 3':5'-cyclic nucleotide phosphodiesterase activities in neuroblastoma lines under differentiating conditions.. Int J Dev Neurosci 15(3):309-19 PMID: 9253655
- 8. Kazmierczak BI. 2017. Synthesis of [(32)P]-c-di-GMP for Diguanylate Cyclase and Phosphodiesterase Activity Determinations.. Methods Mol Biol 1657:23-29 PMID: 28889283
